Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Between the old and new screenshots, core trial information (title, conditions, eligibility criteria, endpoints, enrollment location, and contact) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T13:42:19.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    31 days ago
    Change Detected
    Summary
    Added a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.
    Difference
    5%
    Check dated 2025-10-06T04:25:00.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    The page now shows a new version (v3.1.0) and includes a contact/identifier entry, while the old version reference (v3.0.2) is removed.
    Difference
    0.1%
    Check dated 2025-09-28T23:42:31.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Updated from v3.0.1 to v3.0.2 and removed the 'Back to Top' control.
    Difference
    0.3%
    Check dated 2025-09-14T18:42:44.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.
    Difference
    0.3%
    Check dated 2025-09-07T13:05:25.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name, location details, and specific drug information for Fruquintinib, HMPL-013, and sintilimab, while removing extensive disease categories and previous location terms.
    Difference
    3%
    Check dated 2025-08-31T03:45:29.000Z thumbnail image

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.